MedPacto, Inc.

KOSDAQ 235980.KQ

MedPacto, Inc. Debt to Equity Ratio for the year ending December 31, 2023: 0.03

MedPacto, Inc. Debt to Equity Ratio is 0.03 for the year ending December 31, 2023, a -98.41% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

MedPacto, Inc. Debt to Equity Ratio for the year ending December 31, 2022 was 2.15, a 23.93% change year over year.
MedPacto, Inc. Debt to Equity Ratio for the year ending December 31, 2021 was 1.74, a 16,052.79% change year over year.
MedPacto, Inc. Debt to Equity Ratio for the year ending December 31, 2020 was 0.01, a 5.93% change year over year.
MedPacto, Inc. Debt to Equity Ratio for the year ending December 31, 2019 was 0.01.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

KOSDAQ: 235980.KQ

MedPacto, Inc.

CEO	Mr. Seong-Jin Kim
IPO Date	Dec. 19, 2019
Location	South Korea
Headquarters	Borim Building
Employees	57
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

MedPacto, Inc., a drug discovery and development company, develops and delivers therapeutics targeting cancer and autoimmune diseases in South Korea. The company is developing ME-1601mAb that targets BSP1 for cancers; MS-1601A that targets TRG1 for cancers and autoimmune diseases; and vactosertib for solid tumors. MedPacto, Inc. is based in Seoul, South Korea.

Key trends

Past 5 years